Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery
• TIL Therapy Development
  • Special TIL Therapy Development

CellRapeutics™ Next-Generation TIL Development Services

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

In the field of cancer treatment, tumor-infiltrating lymphocyte (TIL) therapy has emerged as a promising cutting-edge immunotherapy. To better fight against cancer, Creative Biolabs is proud to introduce its CellRapeutics™ next-generation TIL development services. Using our self-developed CAR-TIL/TCR-TIL construction platform, we can quickly design and produce TIL cells that target specific tumor antigens.

Introduction

TIL therapy has been regarded as an innovative strategy for cancer immunotherapy that has garnered increasing attention in recent years. TILs typically possess a strong ability to recognize and respond to tumors, which makes them potentially very effective in treating certain resistant or advanced cancers.

Creative Biolabs offers a comprehensive range of services for CellRapeutics™ Next-Generation TIL development, which includes the establishment and characterization of tumor cell lines, isolation and culture of T cells, immune assays, and functional evaluations. Initially, we assist clients in creating suitable models to ensure the efficacy and safety of TIL therapies. Moreover, we provide precise animal studies targeting various cancer types, assessing the anti-tumor effects of TILs and their underlying mechanisms. Furthermore, we can support drug metabolism, toxicology assessments, and statistical analysis of preclinical data, establishing a solid foundation for subsequent clinical trials. By collaborating closely with us, our clients can accelerate the development process of TIL therapies, enhance success rates, and offer more

1. Sample Collection

- Acquisition of Tumor Tissue: Tumor tissue samples are obtained from patients, typically through surgical procedures or biopsies.

- Pathological Assessment: The tumor tissue is subjected to pathological evaluation to confirm the type of cancer and its characteristics.

2. Isolation and Expansion of TILs

- Isolation of TILs: Lymphocytes are isolated from the tumor tissue using mechanical or enzymatic methods, with collagenase digestion being a common technique.

- Expansion Culture: The isolated TILs are cultured in specific media, often supplemented with cytokines (like IL-2) to enhance lymphocyte proliferation.

3. Phenotypic Analysis of TILs

- Flow Cytometry Analysis: Flow cytometry is employed to analyze the surface markers of TILs, providing insights into their functional state and subpopulation composition.

- Cell Function Testing: The ability of TILs to secrete cytokines, exhibit cytotoxicity, and proliferate is assessed to evaluate their anti-tumor potential.

4. Gene Modification of TILs

- Gene Editing Techniques: Gene editing technologies can be utilized to modify TILs, enhancing their anti-tumor capabilities, for instance, by introducing specific TCRs.

Fig.1 Tumour-infiltrating Lymphocytes for Cell Therapy Development.^1,3

Services

Nowadays, Creative Biolabs combines TIL with other similar cell therapies, such as CAR-T and TCR-T, to explore their synergistic effects and maximize anti-tumor efficacy. With the progress in CellRapeutics™ Next-Generation TIL therapy, we can also provide comprehensive CRO services that encompass everything from cell culture and expansion to cell phenotyping, functional assessment, and research involving animal models.

CellRapeutics™ Next-Generation CAR-TIL Development Services

In the development of CAR-TIL therapy, Creative Biolabs offers cell engineering services that encompass gene editing, plasmid construction, and transfection methods to generate T cells with anti-tumor properties. Our laboratory specializes in collecting tumor samples and expanding lymphocytes. We provide services that include the identification of highly effective tumor-infiltrating lymphocytes (TILs), performing clonal expansion, and assessing their cytotoxicity and specificity. Moreover, we conduct both in vitro and in vivo functional evaluations, employing animal (mouse) models to assess the efficacy and safety of CAR-TIL cells, in addition to carrying out pharmacokinetic and biodistribution studies aimed at refining treatment strategies.

CellRapeutics™ Next-Generation TCR-TIL Development Services

For the construction of TCR-TIL, Creative Biolabs can isolate TIL from various tumor tissue samples. Our scientists are dedicated to optimizing the conditions for the in vitro cultivation of TIL and conducting functional assessments. By evaluating the response capability of TIL against tumor cells, we can assist our clients in selecting the most promising cell populations. Additionally, CBL offers services for target antigen screening and TCR engineering to ensure specificity and effectiveness. We conduct cell culture and expansion using advanced bioreactor technology, which allows for the large-scale production of high-purity engineered T cells. Furthermore, we can provide a variety of functional assays, such as tests for cytotoxicity, cytokine secretion, and proliferation capacity.

Fig.2 FACS Examination of TIL Populations in Mice with CT26 Tumors.^2,3

Features

• Multi-Targeted Attack Capacity: Our service allows for simultaneous targeting of multiple sites on cancer cells, enhancing the effectiveness of treatment.
• Enhanced Anti-Tumor Immune Response: It boosts the activity and longevity of immune cells, improving the overall anti-tumor immune response.
• Overcoming Drug Resistance: It can help reduce drug resistance, as tumor cells may still be sensitive to other antigens even if one has been recognized by the immune system.
• Mitigating Tumor Microenvironment Inhibition: Different types of TIL development strategies can better modulate the tumor microenvironment, enhancing the anti-tumor efficacy of immune cells at the tumor site.
• Improving Clinical Efficacy: It has the potential to increase tumor response rates and prolong survival, particularly in hard-to-treat solid cancers, which may significantly enhance patient prognosis.

As a leader in the industry, Creative Biolabs offers next-generation TIL development services under the CellRapeutics™ brand. We employ advanced cell separation and amplification techniques to guarantee the collection of highly pure TIL and CAR-T/TCR-T cells. Our high-throughput screening technology allows us to rapidly identify and select TILs with the most effective anti-tumor activity. Please feel free to contact us with any questions you may have.

References

1. Morotti, Matteo, et al. "Promises and challenges of adoptive T-cell therapies for solid tumors." British journal of cancer 124.11 (2021): 1759-1776.
2. Goggi, J. L., et al. "Granzyme B PET imaging of immune checkpoint inhibitor combinations in colon cancer phenotypes." Molecular imaging and biology 22 (2020): 1392-1402.
3. Distributed under Open Access license CC BY 4.0, without modification.